Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opti-DOR: DOR/3TC/TDF vs DTG/TAF/FTC in First-line HIV-1
NCT05924438Phase 3Active, not recruiting
- Start
- Nov 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of doravirine in human immunodeficiency virus type 1 infection (HIV-1). Started Nov 2023; status: active, not recruiting.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05924438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924438.